Eisai’s Ontak sBLA Granted U.S. FDA Approval
This article was originally published in PharmAsia News
Executive Summary
TOKYO - U.S. FDA granted full approval to Eisai's biologic Ontak (denileukin) for intravenous injection for treating a recurrent type of lymph node cancer, cutaneous T-cell lymphoma in patients whose malignant cells express the CD25 component of the interleukin-2 receptor